• Derma Sciences Inc., of Princeton, N.J., said it closed its public offering of about 3.5 million shares priced at $10.34 apiece, including the exercise of the underwriters' option to purchase 459,300 shares to cover overallotments. Net proceeds totaled about $33.8 million and will be used to support continued development of DSC127 for the treatment of diabetic foot ulcers, as well as for general corporate purposes.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter